ClinicalTrials.gg
Active, not recruitingNCT07279909Updated Dec 12, 2025

Phase-III Clinical Studies on Poly Herbal Anti-Diabetic Formulation

A Phase 3 interventional study of DIAB-PHC1 and Metformin in Diabetes Type 2, Diabetes Mellitus, Experimental and HbA1c, sponsored by Hamdard University. Active, not recruiting at 1 site in Pakistan. Open to participants aged 30 Years and older. Per ClinicalTrials.gov, last updated 2025-12-12.

Sponsored by Hamdard University · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year 8 months after the study started (first participant enrolled Mar 2024, registered Dec 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
500
Allocation
Non-randomized
Ages
30 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 98 studies in Diabetes Mellitus, Type 2 with a site in Pakistan — 28 open to participants now, 35 under way, 2 of them phase 3. Diabetes Mellitus, Type 2 · Pakistan.

Enrollment
9th of 89
500 · median 99
Started
2024
with 13 others
Phase 3
2 of 98
1 open now
Primary completion
2025-08
later than 9 of 34 live
Registered
76th of 98
by date

Among the 98 studies in Diabetes Mellitus, Type 2 with a site in Pakistan, this one is the 9th largest by enrollment of the 89 interventional ones that give a count, is one of 14 that started in 2024, is one of 2 in phase 3, reaches primary completion later than 9 of the 34 other live ones, and was the 76th registered.

Diabetes Mellitus, Type 2

10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

28 of the 98 studies in Diabetes Mellitus, Type 2 with a site in Pakistan are open now. Recruiting first, the newest first:

23 more — sign in →

All 28 open studies →

A study can be open while its sites in Pakistan have not opened yet or have stopped. Only those recruiting at a site in Pakistan →

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 30 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 98 studies in Diabetes Mellitus, Type 2 with a site in Pakistan, or all of them as a file.
02

Study summary

The goal of this clinical trial to learn the clinical efficacy and safety of standardized polyherbal capsule weighing around 500 mg, containing Syzygium cumini, Momordica charantia, Wrightia tinctoria, and Gymnema sylvestre in equal proportions for controlling Diabetic hyperglycemia towards a normal glycemic control. The main question that aims to search is

  1. Does the herbal combination formula effective to lower the high blood glucose levels in Type2 diabetics
  2. Is the herbal combination therapy is safe for human use
  3. Does this treatment plan reduces the blood sugar level comparative to Metformin 500 mg TID The trial is also comparing its efficacy in comparison to a standard anti diabetic drug Metformin In the study wing, the volunteer diabetic patients will take the herbal capsule 500mg TID and in the control group the volunteer patients will take Metformin 500 mg TID.

    • The recruited patients will continue the assigned therapy for at least six months
    • They visit the clinical trial OPDs fortnightly
    • They will record their fasting blood glucose with the glucometer at least two to three times a week and get the basal tests done in three-month time
Read the detailed description

Preclinical evaluation studies including stability, dissolution and anti-microbial testing were performed. The formulation was also subjected to gas chromatography-mass spectrometry (GCMS). The powdered formulation was analyzed for LD-50 followed by two-center, unblinded, non-randomized controlled clinical trial with convenient sampling was conducted over 24 weeks in 500 adults with T2DM (HbA1c 7.5-10%). Participants were assigned to receive either polyherbal capsules (\~500 mg three times daily, n = 250) or metformin (500 mg three times daily, n = 250). Primary outcome was HbA1c reduction; secondary outcomes included fasting/postprandial glucose, urinary protein, urinary glucose, lipid profile, body weight, and safety. Statistical analyses were performed using two-way ANOVA and unpaired t-tests.

03

Conditions studied

  • Diabetes Type 2
  • Diabetes Mellitus, Experimental
  • HbA1c
  • Urinary Glucose
  • Ability of Experimental Drug to Lower HbA1c Compare to Metformin

Keywords

  • Polyherbal formulation
  • GCMS
  • Syzygium cumini
  • Momordica charantia
  • Wrightia tinctoria,
  • Gymnema sylvestre,
04

Who can participate

Ages eligible
30 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients having Type II Diabetes Mellitus.
  • Patients agree willingly to use study medicine throughout the study
  • Patients having raised FBS above 120 mg/dl and level 6.7 or above.
  • Patients over 30 years of age.
  • Patients of both genders will be included in the study.

Exclusion criteria

Exclusion Criteria:

  • Patients who do not agree willingly to participate in research.

    • Patients having history of any chronic organ failure.
    • Patients having history of any amputation.
    • Patients having history of treated or diagnosed cancer of any organ.
    • Pregnant and lactating mothers.
    • Patients who are having brittle Diabetes
    • Known under treatment cases of psychiatric disorders
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
500 participants (actual)

Study arms

  • Active comparator
    Metformin - control are of the study

    Metformin is standardized hypoglycemic agent with global accepted efficacy \& safety

    Drug: Metformin

  • Experimental
    DIAB-PHC1 - Treatment arm of the study

    The investigational formulation consisted of Syzygium cumini, Momordica charantia, Wrightia tinctoria and Gymnema sylvestre. Raw plant materials were procured from local herbal markets and authenticated shade dried and powdered. The powder was capsulated with avverage weight of 500 mg /capsule. Capsules were given TID with meals to the patients

    Drug: DIAB-PHC1

Interventions

  • DrugDIAB-PHC1

    a novel poly-herbal hard gelatin capsule formulation comprising Syzygium cumini, Momordica charantia, Wrightia tinctoria, and Gymnema sylvestre in a scientifically optimized ratio. Although each of these herbs is traditionally recognized for its individual anti-diabetic activity, their combination in a standardized dosage form has not previously been reported. The study further strengthens its novelty by conducting comprehensive pre-clinical safety evaluations, confirming the absence of toxicity before proceeding to controlled clinical investigations.

  • Standard oral hypoglycemic comparator

    Also known as: Glucophage

06

What researchers measure

Primary outcomes

  1. glycated hemoglobin (HbA1c)

    The primary objective is to assess improvements in glycated hemoglobin (HbA1c) and fasting/ post-prandial plasma glucose.

    Time frame: From two weeks to six months time period

Secondary outcomes

  1. Urinary Proteins

    The secondary objectives are to evaluate reduction in the amount of proteins in urine

    Time frame: At least Six months

  2. Urinary Glucose

    regular check for the urinary glucose levels as a parameter for improved glycemic control

    Time frame: 6 months

07

Study locations

1 site
  • Mehboob Faryal Diagnostic Center
    Karachi, Sindh 74700, Pakistan
08

References and documents

Related links

Individual participant data

Plan to share: No — to keep the privacy \& anonymity of the individual participant of the study, as committed at the time of induction

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2024 to primary completion in Aug 2025, 16 months.

Of 87 non-industry phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 47. This study's 16 months is below that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2025
First posted
Dec 12, 2025
StartActual
Mar 9, 2024
Primary completionActual
Aug 1, 2025
CompletionEst.
May 20, 2026
Last update
Dec 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07279909
Lead sponsor
Hamdard University
Collaborators
Jinnah Postgraduate Medical Centre
Responsible party
Abdul Bari (Head of Clinical Trials, Hamdard University) — Principal investigator
First posted
Dec 12, 2025
Start date
Mar 9, 2024
Primary completion
Aug 1, 2025
Completion
May 20, 2026 (estimated)
Last update
Dec 12, 2025

Study contacts

Mehboob Alam, PhD
study director · Department of Pharmacology, Institute of Basic Medical Sciences, JPMC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion